Edwards Lifesciences Corporation (NYSE:EW - Get Free Report) VP Donald Bobo, Jr. sold 24,000 shares of the stock in a transaction on Wednesday, February 25th. The stock was sold at an average price of $83.84, for a total value of $2,012,160.00. Following the completion of the sale, the vice president owned 21,266 shares in the company, valued at approximately $1,782,941.44. The trade was a 53.02% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.
Edwards Lifesciences Stock Up 2.9%
Shares of NYSE EW opened at $85.83 on Friday. The stock's fifty day simple moving average is $82.72 and its two-hundred day simple moving average is $81.16. Edwards Lifesciences Corporation has a 12-month low of $65.94 and a 12-month high of $87.89. The company has a current ratio of 4.00, a quick ratio of 3.29 and a debt-to-equity ratio of 0.06. The stock has a market capitalization of $49.81 billion, a PE ratio of 46.90, a price-to-earnings-growth ratio of 2.18 and a beta of 0.94.
Edwards Lifesciences (NYSE:EW - Get Free Report) last announced its quarterly earnings data on Tuesday, February 10th. The medical research company reported $0.58 EPS for the quarter, missing the consensus estimate of $0.62 by ($0.04). The company had revenue of $1.57 billion during the quarter, compared to analysts' expectations of $1.54 billion. Edwards Lifesciences had a net margin of 17.69% and a return on equity of 14.50%. The business's revenue for the quarter was up 13.3% compared to the same quarter last year. During the same period in the previous year, the business earned $0.59 earnings per share. Edwards Lifesciences has set its Q1 2026 guidance at 0.700-0.760 EPS. As a group, analysts expect that Edwards Lifesciences Corporation will post 2.45 EPS for the current fiscal year.
Wall Street Analyst Weigh In
EW has been the topic of a number of analyst reports. JPMorgan Chase & Co. upgraded Edwards Lifesciences from a "neutral" rating to an "overweight" rating and lifted their price objective for the stock from $90.00 to $100.00 in a research report on Thursday, December 18th. Weiss Ratings reissued a "hold (c)" rating on shares of Edwards Lifesciences in a research note on Wednesday, January 21st. BTIG Research reaffirmed a "buy" rating and issued a $103.00 price target on shares of Edwards Lifesciences in a research report on Wednesday, February 11th. Sanford C. Bernstein reaffirmed a "market perform" rating and set a $90.00 price objective on shares of Edwards Lifesciences in a research report on Monday, November 3rd. Finally, Citigroup reissued a "buy" rating and set a $101.00 price objective (up from $96.00) on shares of Edwards Lifesciences in a report on Thursday, December 11th. Three investment analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and nine have assigned a Hold rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $96.14.
Check Out Our Latest Analysis on Edwards Lifesciences
Hedge Funds Weigh In On Edwards Lifesciences
A number of large investors have recently bought and sold shares of EW. MidFirst Bank purchased a new stake in shares of Edwards Lifesciences during the 4th quarter valued at about $298,000. Kera Capital Partners Inc. lifted its holdings in shares of Edwards Lifesciences by 8.8% in the 4th quarter. Kera Capital Partners Inc. now owns 6,006 shares of the medical research company's stock worth $489,000 after purchasing an additional 488 shares during the last quarter. MV Capital Management Inc. acquired a new position in shares of Edwards Lifesciences during the fourth quarter worth approximately $26,000. Compound Planning Inc. increased its holdings in shares of Edwards Lifesciences by 20.9% during the fourth quarter. Compound Planning Inc. now owns 3,921 shares of the medical research company's stock valued at $334,000 after purchasing an additional 678 shares during the period. Finally, Harbour Wealth Management Group Inc. acquired a new stake in shares of Edwards Lifesciences in the 4th quarter worth approximately $237,000. Hedge funds and other institutional investors own 79.46% of the company's stock.
Edwards Lifesciences Company Profile
(
Get Free Report)
Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.
In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
